Idiopathic venous thromboembolism or occult cancer?

• Authors: Szymon Darocha , Michał Florczyk , Adam Torbicki
• Languages of publication: EN

Abstracts

EN

The relationship between cancer and an increased incidence of venous thromboembolism (VTE) is well documented. VTE is a common complication of cancer, which usually occurs in the advanced stages of the disease. It often manifests itself before the cancer has been diagnosed and frequently is the first symptom of malignancy. In particular, pulmonary embolism is a major epidemiological problem because of its prevalence and high mortality. This article contains a review of the literature on VTE and occult cancer. It indicates the problem of a lack of an effective diagnostic strategy for malignancy in patients with idiopathic venous thromboembolism.

Keywords

EN

pulmonary embolism; screening for occult cancer; venous thromboembolism

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OncoReview
• Year: 2014
• Volume: 4
• Issue: 1
• Pages: A5-10

Contributors

author

Szymon Darocha

• Department of Pulmonary Circulation and Thromboembolic Diseases, Center of Postgraduate Medical Education, ECZ-Otwock

author

Michał Florczyk

• Department of Pulmonary Circulation and Thromboembolic Diseases, Center of Postgraduate Medical Education, ECZ-Otwock

author

Adam Torbicki

• Department of Pulmonary Circulation and Thromboembolic Diseases, Center of Postgraduate Medical Education, ECZ-Otwock

References

• Blom JW, Doggen CJ, Osanto S et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-722.
• Chew HK, Wun T, Harvey D et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166: 458-464.
• Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 2000; 83: 657-660.
• Stein PD, Kayali F, Olson RE. Estimated case fatality rate of pulmonary embolism, 1979 to 1998. Am J Cardiol 2004; 93: 1197-1199.
• Kurzyna M. Assessment of the accuracy of diagnostics of acute pulmonary embolism and its impact on the prognosis of patients hospitalised in the Polish cardiology centres. Analysis of the ZATPOL registry results. Postdoctoral thesis.
• Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353: 1386-1389.
• Heit JA, O’Fallon WM, Petterson TM et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a populationbased study. Arch Intern Med 2002; 162: 1245-1248.
• Cushman M, Tsai A, Heckbert SR et al. Incidence rates, case fatality, and recurrence rates of deep vein thrombosis and pulmonary embolus: the Longitudinal Investigation of Thromboembolism Etiology (LITE). Thromb Haemost 2001; 86(suppl 1): OC2349. Abstract.
• White RH, Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med 1998; 128: 737-740.
• Koopman MMW, Prandoni P, Piovella F et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334: 682-7.
• Hettiarachchi RJ, Lok J, Prins MH et al. Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. Cancer 1998; 83: 180-185.
• Murchison JT, Wylie L, Stockton DL. Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study. Br J Cancer 2004; 91: 92-95.
• Prandoni P, Lensing AW, Buller HR et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327: 1128-1133.
• Sorensen HT, Mellemkjaer L, Steffensen FH et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998; 338: 1169-1173.
• White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003; 90: 446-455.
• Nordstrom M, Lindblad B, Anderson H et al. Deep venous thrombosis and occult malignancy: an epidemiological study. BMJ 1994; 308: 891-4.
• Baron JA, Gridley G, Weiderpass E et al. Venous thromboembolism and cancer. Lancet 1998; 351: 1077-80.
• Van Doormaal FF, Terpstra W, van der Griend R et al. Is extensive screening for cancer in idiopathic venous thromboembolism warranted? J Thromb Haemost 2011; 9: 79-84.
• Monreal M, Lensing AW, Prins MH et al. Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Thromb Haemost 2004; 2: 876-81.
• Rieu V, Chanier S, Philippe P et al. Systematic screening for occult cancer in elderly patients with venous thromboembolism: a prospective study. Intern Med J 2011; 41(11): 769-75.
• Piccioli A, Lensing AW, Prins MH et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost 2004; 2: 88409.
• Di Nisio M, Otten HM, Piccioli A et al. Decision analysis for cancer screening in idiopathic venous thromboembolism. J Thromb Haemost 2005; 3: 2391-6.
• Beckers MM, Verzijlbergen JF, van Buul MM et al. The potential role of positron emission tomography in the detection of occult cancer in 25 patients with venous thromboembolism. Ann Oncol 2008; 19(6): 1203-4.
• Chen YK, Ding HJ, Su CT et al. Application of PET and PET/CT imaging for cancer screening. Anticancer Res 2004; 24(6): 4103-8.
• Schöder H, Gonen M. Screening for cancer with PET and PET/CT: potential and limitations. J Nucl Med 2007; 48(suppl 1): 4S-18S.
• Sioka C, Fotopoulos A, Kyrytsis AP. Paraneoplastic neurological syndromes and the role of PET imaging. Oncology 2010; 78(2): 150-6.
• Rondina MT, Wanner N, Pendleton RC et al. A pilot study utilizing whole body 18F-FDG-PET/CT as a comprehensive screening strategy for occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research 2012; 129: 22-27.
• Wagner JL. Cost-effectiveness of screening for common cancers. Cancers Metastasis Rev 1977; 16(3-4): 281-94.
• Tengs TO, Adams ME, Pliskin JS et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995; 15(3): 369-90.
• Mandala M, Falanga A, Roila F on behalf of the ESMO Guidelines Working Group, „Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines”, Annals of Oncology 2011; 22(suppl 6): vi85-vi92.

• Document Type: article